Current

Caristo Diagnostics

Life Sciences

•

South East

•

Early Stage

•

2020

Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.

Caristo was founded in 2018 by cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention.

To date, the company has raised a total of £10.2 million. It recently closed a successful investment round led by BGF and existing investors, including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).

Looking for funding?

We’ve already helped hundreds of ambitious businesses in the UK and Ireland to accelerate their growth. If you’re looking for a minority investment partner that can provide long-term, flexible funding and support, please get in touch with our team today.

Introduce yourself

Caristo Diagnostics

Looking for funding?

Similar companies